Mathew Essa

A global motion picture franchise based on the best-selling novel series by Nova McBee.

Introducing Atom Touch — the first artificial human arm.

EnGen is an early-stage biotechnology company pioneering a new approach to preventing and treating influenza. We're developing an effective, easy-to-manufacture, shelf-stable universal flu vaccine that confers long-term immunity to all Type A influenza strains—including those which cause seasonal flu and influenza pandemics. Seasonal flu causes 250,000 to 500,000 deaths every year. The CDC and other experts have cautioned that we are extremely vulnerable to the catastrophic occurrence of a global flu pandemic—on a scale that could far exceed both COVID-19 and the Spanish flu of 1918. In its Global Influenza Strategy (2019–2030) report, the World Health Organization has declared the development of a universal flu vaccine as an urgent need—but the unique nature and genetic makeup of the influenza virus poses a challenge to researchers focused on influenza treatment and vaccination. To address these issues, EnGen Bio is developing universal vaccines for Type A flu prevention. Effective for vaccination in both the $6B human and $0.5B veterinary markets, our antibodies also demonstrate potential for therapeutic treatment of influenza, with an additional $2B prospective market. If successful, our efforts will eradicate flu pandemics and dramatically decrease the global burden of illness and disease caused by influenza.

SolarGaps opens your window to free energy. We offer a simple Smart Blinds solution that automatically tracks the sun and generates electricity. Simply plug-in SolarGaps and solar energy starts to power all devices in your home! It can even store power in your home battery storage solution. With SolarGaps, you make your own electricity. Through our smartphone app you can monitor and control SolarGaps from anywhere in the world. "We believe that green energy should be available for every body."​ - Yevgen Erik, Founder of SolarGaps

Mercury is the fintech ambitious companies use for banking* and all their financial workflows. With a powerful account at the center of their operations, companies can make better financial decisions and ensure that every dollar spent aligns with company priorities. Thats why over 300K startups choose Mercury to confidently run all their financial operations with the precision, control, and focus they need to operate at their best. To learn more, visit Mercury.com. *Mercury is a fintech company, not an FDIC-insured bank. Banking services provided through Choice Financial Group and Column N.A., Members FDIC.

Suvon Fragrances™ is the first Kuwait-based fragrance house built around SCENTAI™, our proprietary AI engine for personalized scent creation. We offer two experiences: The Originals™, five signature fragrances rooted in Gulf olfactory tradition, and the SCENTAI™ Experience, a 15-minute, AI-guided session, available in English and Arabic, that formulates a bespoke, non-alcohol fragrance made only after it is chosen. Every bottle we produce is made to order. Every box and bottle we sell is designed to be returned to us for recycling. We believe personalization and sustainability should be built into a fragrance brand from day one.

We’re the Robinhood for pre-IPO startups. Everyone can angel invest $100 in a Community Round. On May 16, 2016, it became legal for everyday people to invest as little as $100 in startups and small businesses. Since then, we’ve helped 1,860 founders raise almost $500M from their community - for flying cars, coffee shops, and everything in between. We’re a Public Benefit Corporation with a mission to revitalize capitalism and keep the American dream alive. GDP growth is slowing. Wealth inequality is increasing. Entrepreneurship is dying across America; falling from 10.6% to 3.6% among those under 30 since 1989. We’re reversing these trends by funding more deserving businesses across all of America, not solely tech startups in Silicon Valley. Want to help? Join us! We’re a team of founder types: enjoy autonomy, responsibility, the opportunity to learn, and no red tape. Just make it happen.

A global motion picture franchise based on the best-selling novel series by Nova McBee.

Introducing Atom Touch — the first artificial human arm.

EnGen is an early-stage biotechnology company pioneering a new approach to preventing and treating influenza. We're developing an effective, easy-to-manufacture, shelf-stable universal flu vaccine that confers long-term immunity to all Type A influenza strains—including those which cause seasonal flu and influenza pandemics. Seasonal flu causes 250,000 to 500,000 deaths every year. The CDC and other experts have cautioned that we are extremely vulnerable to the catastrophic occurrence of a global flu pandemic—on a scale that could far exceed both COVID-19 and the Spanish flu of 1918. In its Global Influenza Strategy (2019–2030) report, the World Health Organization has declared the development of a universal flu vaccine as an urgent need—but the unique nature and genetic makeup of the influenza virus poses a challenge to researchers focused on influenza treatment and vaccination. To address these issues, EnGen Bio is developing universal vaccines for Type A flu prevention. Effective for vaccination in both the $6B human and $0.5B veterinary markets, our antibodies also demonstrate potential for therapeutic treatment of influenza, with an additional $2B prospective market. If successful, our efforts will eradicate flu pandemics and dramatically decrease the global burden of illness and disease caused by influenza.